Avidity Partners Management LP - Q3 2019 holdings

Add to watchlist

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
No holdings reported for quarter Q3 2019
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES INC15Q3 20234.6%
ARVINAS INC14Q3 20234.9%
ZENTALIS PHARMACEUTICALS INC14Q3 20234.8%
SYNDAX PHARMACEUTICALS INC14Q3 20233.2%
IDEAYA BIOSCIENCES INC13Q3 20232.5%
NATERA INC13Q3 20231.9%
ALPINE IMMUNE SCIENCES INC13Q3 20230.5%
ABBVIE INC12Q2 20239.7%
HORIZON THERAPEUTICS PUB LTD12Q3 20223.4%
AVANTOR INC11Q1 20236.0%

View Avidity Partners Management LP's complete holdings history.

Latest significant ownerships (13-D/G)
Avidity Partners Management LP Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adicet Bio, Inc.Sold outFebruary 14, 202300.0%
ALPINE IMMUNE SCIENCES, INC.February 14, 20231,888,8874.0%
ESSA Pharma Inc.February 14, 20231,855,4004.2%
Gritstone bio, Inc.February 14, 20232,859,9713.3%
IVERIC bio, Inc.February 14, 2023838,4070.6%
ONCOSEC MEDICAL IncSold outFebruary 14, 202300.0%
PhaseBio Pharmaceuticals IncFebruary 14, 20232,040,0004.1%
Phathom Pharmaceuticals, Inc.February 14, 20231,900,0004.6%
Viridian Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Anika Therapeutics, Inc.Sold outFebruary 14, 202200.0%

View Avidity Partners Management LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-09
SC 13G2024-03-27
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13

View Avidity Partners Management LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Avidity Partners Management LP's holdings

CSVXLS